Developer docs
API playgroundTry for free, no card

Search company profiles

Exvastat

Full company profile

uuid00046g8

Namestring
Exvastat
Websiteurl
exvastat.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Exvastat is a preclinical-stage pharmaceutical company founded in 2016 and headquartered in Cambridge, United Kingdom. The company operates with a very small team of 1-10 employees and is classified as private, indicating an early-stage drug discovery operation that has not yet reached clinical trials or commercialization.

The company's activities are positioned within the early-stage pharmaceutical R&D value chain, where it likely focuses on target identification, compound development, and preclinical validation. Its capital structure reflects this stage: an initial 2017 funding round led by Cambridge Innovation Capital (a specialist UK life sciences investor) was followed in May 2020 by approximately $3.9 million from the Innovative Medicines Initiative (IMI), the EU's public-private partnership for pharmaceutical research. The IMI funding in particular suggests integration into multi-partner European preclinical research consortia.

Exvastat is led by co-founder and CEO David Cavalla, supported by co-founder Andrew McElroy as Strategic Project Manager, CFO Stuart Gibson, and Non-Executive Director Julian Gilbert. With no disclosed revenue, pricing model, commercial products, or named customers, the company's business model at present is grant- and equity-funded preclinical R&D rather than product sales; future revenue mechanics will depend on out-licensing, partnerships, or eventual clinical progression of any candidates.

Short descriptiontext

Exvastat is a preclinical-stage, privately held pharmaceutical company founded in 2016 in Cambridge, UK, developing early-stage drug candidates with a small founder-led team funded by Cambridge Innovation Capital and the EU's Innovative Medicines Initiative.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
preclinical drug development, pharmaceutical research, drug discovery services, early-stage biopharma, small molecule therapeutics
Industry1 code
PRIMARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Preclinical Pharmaceutical Research
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Exvastat is a preclinical-stage pharmaceutical company that conducts early-stage drug discovery and development research. Founded in 2016 and based in Cambridge, United Kingdom, the company operates with a small team (1-10 employees) focused on advancing innovative therapeutic candidates prior to clinical trials.

Differentiator
Functional benefit
Problem solved
Partnership1 partner
Strategic tierUnclearTypeStrategic or Co-development Partner
Description

Harumslot works with official platforms to provide fast access with secure and trusted connections. The platform collaborates with official partners to ensure rapid and safe access for users.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cambridge, UK-based preclinical-stage biotech developing T-cell engager biologics. Comparable to Exvastat in Cambridge location, preclinical stage, and small-team operating model focused on a defined therapeutic platform.

TypeBroad incumbent
Description

Global pharmaceutical company with a major R&D footprint in Cambridge, UK. Comparable to Exvastat as a Cambridge-anchored pharma operator and a likely IMI-consortium industry partner; represents the type of strategic acquirer or partner relevant to Exvastat's forward optionality.

TypeBroad incumbent
Description

Large contract research organization providing preclinical discovery and development services across small molecules and biologics. Comparable to Exvastat as a counterpart for outsourced preclinical work and as a benchmark for the broader preclinical-services value chain Exvastat operates within.

TypeBroad incumbent
Description

Global pharmaceutical company headquartered in the UK with a major Cambridge-area R&D presence and historical involvement in IMI consortia. Comparable to Exvastat as a Cambridge-anchored pharma operator and a likely consortium/partner counterpart for IMI-funded preclinical programs.

TypeDirect peer
Description

Cambridge, UK-headquartered clinical-stage biotech developing novel therapeutics based on bicyclic peptide scaffolds. Comparable to Exvastat as a Cambridge-rooted, small-team pharmaceutical company that progressed from preclinical to clinical development — a relevant trajectory benchmark for Exvastat's forward path.

TypeEmerging player
Description

Cambridge, UK-based drug-development CRO focused on preclinical and translational work for early-stage biotechs. Comparable to Exvastat as a Cambridge-ecosystem service provider to similar small preclinical pharma companies and as a benchmark for outsourced preclinical execution.

TypeDirect peer
Description

Cambridge, UK-based preclinical/early-clinical biotech developing small-molecule drugs targeting deubiquitinating enzymes. Comparable to Exvastat in Cambridge location, small-team operating structure, and earlier-stage development profile.

TypeBroad incumbent
Description

Global drug-discovery and development services company with deep operations in small-molecule and biologic preclinical work. Comparable to Exvastat as a potential outsourced-discovery counterpart and as a benchmark for capital-efficient preclinical development models.

TypeDirect peer
Description

Cambridge, UK-based preclinical drug-discovery biotech using a proprietary target-identification platform to generate novel therapeutic programs. Highly comparable to Exvastat in geography, stage, and small-team operating model, with a similar early-capital profile.

TypeEmerging player
Description

UK-based CRO with integrated drug-discovery services and a co-discovery model that has produced spin-out biotechs. Comparable to Exvastat as a Cambridge-ecosystem participant offering preclinical services and as an emerging alternative model for asset development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exvastat

Preclinical Pharmaceutical Researchexvastat.com

Exvastat is a preclinical-stage, privately held pharmaceutical company founded in 2016 in Cambridge, UK, developing early-stage drug candidates with a small founder-led team funded by Cambridge Innovation Capital and the EU's Innovative Medicines Initiative.

What Exvastat does

Exvastat is a preclinical-stage pharmaceutical company founded in 2016 and headquartered in Cambridge, United Kingdom. The company operates with a very small team of 1-10 employees and is classified as private, indicating an early-stage drug discovery operation that has not yet reached clinical trials or commercialization.

The company's activities are positioned within the early-stage pharmaceutical R&D value chain, where it likely focuses on target identification, compound development, and preclinical validation. Its capital structure reflects this stage: an initial 2017 funding round led by Cambridge Innovation Capital (a specialist UK life sciences investor) was followed in May 2020 by approximately $3.9 million from the Innovative Medicines Initiative (IMI), the EU's public-private partnership for pharmaceutical research. The IMI funding in particular suggests integration into multi-partner European preclinical research consortia.

Exvastat is led by co-founder and CEO David Cavalla, supported by co-founder Andrew McElroy as Strategic Project Manager, CFO Stuart Gibson, and Non-Executive Director Julian Gilbert. With no disclosed revenue, pricing model, commercial products, or named customers, the company's business model at present is grant- and equity-funded preclinical R&D rather than product sales; future revenue mechanics will depend on out-licensing, partnerships, or eventual clinical progression of any candidates.

Exvastat firmographics

Firmographics
Name
Exvastat
Website
https://exvastat.com
Company type
Private
Founded year
2016
Headcount range
1–10 employees
Short description
Exvastat is a preclinical-stage, privately held pharmaceutical company founded in 2016 in Cambridge, UK, developing early-stage drug candidates with a small founder-led team funded by Cambridge Innovation Capital and the EU's Innovative Medicines Initiative.
Ownership category
akta.pro rank

Exvastat industry classification

Industry
Product category
Preclinical Pharmaceutical Research
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Preclinical drug development
  • Pharmaceutical research
  • Drug discovery services
  • Early-stage biopharma
  • Small molecule therapeutics

Where Exvastat is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Markets served

Exvastat business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Exvastat product offering

Product offering

Core offering

Exvastat is a preclinical-stage pharmaceutical company that conducts early-stage drug discovery and development research. Founded in 2016 and based in Cambridge, United Kingdom, the company operates with a small team (1-10 employees) focused on advancing innovative therapeutic candidates prior to clinical trials.

Differentiator

Problem solved

Functional benefit

Companies that use Exvastat

Customer profile

Ideal customer profiles1 record

Exvastat technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Exvastat partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Official platformsunclearStrategic or Co-development PartnerHarumslot works with official platforms to provide fast access with secure and trusted connections. The platform collaborates with official partners to ensure rapid and safe access for users.

Recent moves2 records

Expansion highlights3 records

Exvastat competitors and assessment

Company assessment

Direct peers

  • Crescendo Biologics: Cambridge, UK-based preclinical-stage biotech developing T-cell engager biologics. Comparable to Exvastat in Cambridge location, preclinical stage, and small-team operating model focused on a defined therapeutic platform.
  • Bicycle Therapeutics: Cambridge, UK-headquartered clinical-stage biotech developing novel therapeutics based on bicyclic peptide scaffolds. Comparable to Exvastat as a Cambridge-rooted, small-team pharmaceutical company that progressed from preclinical to clinical development — a relevant trajectory benchmark for Exvastat's forward path.
  • Mission Therapeutics: Cambridge, UK-based preclinical/early-clinical biotech developing small-molecule drugs targeting deubiquitinating enzymes. Comparable to Exvastat in Cambridge location, small-team operating structure, and earlier-stage development profile.
  • PhoreMost: Cambridge, UK-based preclinical drug-discovery biotech using a proprietary target-identification platform to generate novel therapeutic programs. Highly comparable to Exvastat in geography, stage, and small-team operating model, with a similar early-capital profile.

Broad incumbents

  • AstraZeneca: Global pharmaceutical company with a major R&D footprint in Cambridge, UK. Comparable to Exvastat as a Cambridge-anchored pharma operator and a likely IMI-consortium industry partner; represents the type of strategic acquirer or partner relevant to Exvastat's forward optionality.
  • Charles River Laboratories: Large contract research organization providing preclinical discovery and development services across small molecules and biologics. Comparable to Exvastat as a counterpart for outsourced preclinical work and as a benchmark for the broader preclinical-services value chain Exvastat operates within.
  • GSK: Global pharmaceutical company headquartered in the UK with a major Cambridge-area R&D presence and historical involvement in IMI consortia. Comparable to Exvastat as a Cambridge-anchored pharma operator and a likely consortium/partner counterpart for IMI-funded preclinical programs.
  • Evotec: Global drug-discovery and development services company with deep operations in small-molecule and biologic preclinical work. Comparable to Exvastat as a potential outsourced-discovery counterpart and as a benchmark for capital-efficient preclinical development models.

Emerging players

  • RxCelerate: Cambridge, UK-based drug-development CRO focused on preclinical and translational work for early-stage biotechs. Comparable to Exvastat as a Cambridge-ecosystem service provider to similar small preclinical pharma companies and as a benchmark for outsourced preclinical execution.
  • Domainex: UK-based CRO with integrated drug-discovery services and a co-discovery model that has produced spin-out biotechs. Comparable to Exvastat as a Cambridge-ecosystem participant offering preclinical services and as an emerging alternative model for asset development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Exvastat social profiles

Digital presence

Exvastat financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exvastat leadership team

Management profile

Number of profiles

Profiles4 records

Exvastat funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exvastat M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exvastat

What does Exvastat do?

Exvastat is a preclinical-stage pharmaceutical company that conducts early-stage drug discovery and development research. Founded in 2016 and based in Cambridge, United Kingdom, the company operates with a small team (1-10 employees) focused on advancing innovative therapeutic candidates prior to clinical trials.

When was Exvastat founded?

Exvastat was founded in 2016. It employs 1 to 10 people.

Where is Exvastat based?

Exvastat is headquartered in Cambridge, United Kingdom, in the Europe region.

Who are Exvastat's main competitors?

Direct peers on record are Crescendo Biologics, Bicycle Therapeutics, Mission Therapeutics and PhoreMost. Broad incumbents are AstraZeneca, Charles River Laboratories, GSK and Evotec. Emerging players are RxCelerate and Domainex.

Does Exvastat have an API?

No public API is recorded for Exvastat.

What industry is Exvastat in?

Exvastat's product category is Preclinical Pharmaceutical Research. Its primary akta.pro industry code is HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales